Zoetis

One-line summary: The largest pure-play animal-health company (NYSE: ZTS); holds conditional FDA approval for Dectomax-CA1, a doramectin injection formulated for New World screwworm prevention — making it a named beneficiary of the 2026 US screwworm re-establishment, though no source yet quantifies the revenue.

What it is

Zoetis is a US animal-health company spun out of Pfizer, selling vaccines, parasiticides and diagnostics into livestock and companion-animal markets.

Why it matters to stock-market

• Pre-approved therapeutic on a live outbreak. From 2026-07-10-autoresearch-screwworm-outbreak-cattle-herd-squeeze-beneficiaries: "Zoetis (ZTS) holds conditional FDA approval for Dectomax-CA1, a doramectin injection specifically formulated for screwworm prevention. ZTS shares rallied nearly 4% after Texas livestock tested positive for New World screwworm."
• The exposure is unquantified. The same source is explicit: "no analyst quantified incremental revenue in any source fetched… A ~4% move on a conditional approval for one parasite in one state's herd is plausibly sentiment, not earnings. Unquantified." Treat as a narrative-driven move until ZTS sizes it on a call.
• Counter-cyclical to the beef squeeze. Parasiticide demand is set by parasite incidence and geography, not by the cattle cycle — so this is the one leg of the cattle complex that pays whether or not the herd rebuilds.

Related

• screwworm-herd-rebuild-deferral-to-animal-health-rerate — the hypothesis chain.
• cattle-cycle-beef-supply-squeeze — the parent forcing function.
• elanco — the higher-beta expression of the same chain.